Repligen Takes $41.2 Million Charge On Licensed Technology, Then Lines Up $1.0 Billion Convertible Deal

The charge pushed a quarterly operating loss of $29.5 million; a $120.0 million stock buyback rides on the new notes.

Share
Repligen Takes $41.2 Million Charge On Licensed Technology, Then Lines Up $1.0 Billion Convertible Deal

Repligen wrote off a $41.2 million developed technology tied to an intellectual property license, a charge that turned third-quarter operating income of $16.8 million a year earlier into a $29.5 million loss, according to its 10-Q filed Friday. The company then agreed on October 29 to issue $1.0 billion of new convertible notes and use about $120.0 million of the cash to buy back its own stock.

The write-off

Repligen, which makes the filtration, chromatography, process analytics and protein products that drugmakers use to manufacture biologic drugs, said the technology would not generate future undiscounted cash flows and so was not recoverable. An impairment indicator surfaced during the third quarter, and the assets were treated as their own asset group.

The $41.2 million is the entire intangible impairment line for the nine months. The annual goodwill review, done as of October 1, 2026, found no sign of impairment for the company's single reporting unit.

The third-quarter net loss was $38.4 million, or $0.68 a share, against net income of $14.9 million a year earlier. Revenue rose to $209.3 million from $188.8 million, the company reported in its October 27 results.

Refinancing the 2028 notes

Under the agreements, per an 8-K, Repligen will issue $1.0 billion of 0.25% convertible notes due 2031. About $541.4 million of them go to holders swapping in about $456.8 million of its 1.00% notes due 2028, and about $458.6 million are sold for cash.

About $143.2 million of the 2028 notes will remain outstanding with terms unchanged. The company plans to spend about $120.0 million of the cash proceeds buying back shares from some of the new noteholders at $188.64, the October 29 closing price. The notes carry an initial conversion price of about $226.37, a premium of about 20.0%.

The rest of the proceeds is earmarked for working capital and general corporate purposes, including possible acquisitions.

BioLife closes at a higher price

Repligen completed its purchase of BioLife on October 6 for about $1.9 billion, paid with about $564 million in cash and about 7.2 million shares. The earlier quarterly filing put the deal at about $1.5 billion when it was signed.

The risk language shifted with the close: the warning that the deal might not be completed is gone, leaving integration risk. The company ended September with $863 million in cash and marketable securities. Its market value was $12.0 billion in Friday's report.

The note exchange and subscription are expected to close on or about November 6, and BioLife enters Repligen's results with the fourth quarter.

The exchange and subscription are due to close on or about November 6, with BioLife first appearing in fourth-quarter results.

Sources

More on Repligen

All Repligen (RGEN) coverage →